



Kintalk

**Kintalk/LSSN
Collaboration to
Facilitate Research on
Screening for Lynch
Syndrome**



UCSF



PI: Aparajita Singh, MD, MPH
Division of Gastroenterology

DISCLOSURES : None



Co-I: Amie Blanco, MS, LCGC
Director, UCSF Cancer Genetics
and Prevention Program

DISCLOSURES: Spouse is an
employee of Genentech



EMORY
UNIVERSITY

Co-I: Cecelia Bellcross, PhD,
MS,CGC, LSSN Board

DISCLOSURES : None



Home

Promoting Universal Lynch Syndrome Screening

The Lynch Syndrome Screening Network promotes universal tumor screening (UTS) of all individuals with newly diagnosed colorectal and endometrial cancers. Our goal is to

Search

"Empowering Families With Hereditary Cancers Through Communication and Education"



[JOIN NOW](#)

[ABOUT](#)

[NEWS](#)

[GENETICS 101](#)

[SHARING YOUR INFORMATION](#)

[DONATE](#)

[Sign In](#)



Kintalk can help you understand
Hereditary Colon Cancer



Funds

- CGA - \$20,000
 - Rebuilding database
- UCSF - \$10,000
 - Annual hosting fee
- Omni Health Media - \$7500
 - Data transfer & reporting tools





Overarching Goal

- To facilitate the multi-institutional collection of data on universal Lynch Syndrome screening, to evaluate screening and testing strategies and outcomes



Aim 1

Revise & rebuild LSSN
database



Aim 2

Facilitate data collection and
transfer by LSSN members



Aim 3

Answer initial questions,
support further research by
LSSN members




Database Content

- Demographics: age, gender, race, insurance
- Index Cancer
 - Colon – site, specimen type, pathology
 - Endometrial – specimen type, pathology
 - Other LS-related cancers
 - TNM Pathological stage
- Tumor Screening results – MSI, IHC, BRAF methylation
- Previous CA or diagnosis of Lynch syndrome

Database Content – Screen Positive

- Genetic Counseling – if no, reasons
- Family History – limited vs. extensive
- Genetic Testing Performed – germline and somatic, results (variant and pathogenicity)
 - If No - reasons
- If Pathogenic/likely pathogenic
 - Family members tested
 - Results
 - Screening recommendations



Database Features



- Participating institutions can assign data entry, data export, and site administrator privileges
- Access to aggregate data through LSSN research proposal and publication process
- Allows data dumping from existing LSSN member databases
- Use for primary LS Screening data collection
- Reporting tools



Introduction

Welcome to the Lynch Syndrome Screening Network (LSSN) database. Your participation in this important project is greatly appreciated and will assist in fulfilling the LSSN vision of reducing the cancer burden associated with Lynch syndrome.

Please refer to the LSSN Database Manual for instructions and definitions to assist you in accurate data entry. Questions regarding the database or entry should be directed to [Sarah Mango - Mango5@mcnicholn.gov](mailto:Sarah.Mango_S_Mango5@mcnicholn.gov)

Save Exit Delete

Demographics

Patient Code:	Emory_16_27_12_123456		
Age at diagnosis:	55	(if over 80, enter 80 as age)	Location: Emory
Sex:	Male	:	Hispanic/Latino: No
Race 1:	Caucasian	:	Race 2:
Insurance 1:	Private	:	Insurance 2:

Previous or Synchronous Lynch Syndrome-related Cancer

<input checked="" type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown	Age at diagnosis	Cancer type	
	50	Colon	Delete
	51	Rectum	Delete
	<input type="text"/>	<input type="text"/>	Add

Index Cancer

Type: Date:

Specimen Type:

Pathological Features Available: Yes No Unknown

TNM Staging T: N: M: Staging Unknown:

Features:

<input type="checkbox"/> Tumor infiltrating lymphocytes	<input checked="" type="checkbox"/> Endometrioid
<input type="checkbox"/> Crohn's-like lymphocytic reaction	<input type="checkbox"/> Clear Cell
<input type="checkbox"/> Signet Ring cell	<input type="checkbox"/> Papillary Serous
<input type="checkbox"/> Mucinous	<input type="checkbox"/> Mixed histology (endometrial)
<input type="checkbox"/> Medullary growth pattern	<input type="checkbox"/> Transitional Cell
<input type="checkbox"/> None of the above features are noted	

Unusual Screening/Testing Situation Details:

Tumor Screening

MSI Testing: Yes No Attempted/failed

IHC Testing: Yes No Attempted/failed Date: (mm/dd/yy)

Results:

MLH1:	<input type="radio"/> Present	<input checked="" type="radio"/> Absent	<input type="radio"/> Indeterminate	<input type="radio"/> Not done
MSH2:	<input checked="" type="radio"/> Present	<input type="radio"/> Absent	<input type="radio"/> Indeterminate	<input type="radio"/> Not done
MSH6:	<input checked="" type="radio"/> Present	<input type="radio"/> Absent	<input type="radio"/> Indeterminate	<input type="radio"/> Not done
PMS2:	<input type="radio"/> Present	<input checked="" type="radio"/> Absent	<input type="radio"/> Indeterminate	<input type="radio"/> Not done

BRAF V600E Testing: Yes No Attempted/failed Date: (mm/dd/yy)

Result: Positive Negative

MLH1 Promoter Methylation Analysis: Yes No Attempted/failed Date: (mm/dd/yy)

Result: Positive Negative

Genetic Counseling/Testing

Genetic Counseling Completed

Yes No Unknown

Family History:

Positive Negative Unknown

Amsterdam I Criteria Met Yes No

Amsterdam II Criteria Met Yes No

Bethesda Criteria Met Yes No

Basic Family History

1st degree relative with colon cancer Yes No

1st degree relative with endometrial cancer Yes No

1st degree relative with other Lynch cancer Yes No

2nd degree relative with colon cancer Yes No

2nd degree relative with endometrial cancer Yes No

2nd degree relative with other Lynch cancer Yes No

Genetic Testing (DNA Analysis) Performed Yes No Unknown

Gene/Test	Ordered Date	Positive	Mutation	Negative	VUS	Variant	Not Completed
MLH1 seq	11/25/12	<input checked="" type="radio"/>	198insC	<input type="radio"/>	<input type="radio"/>		<input type="radio"/>
MLH1 del/dup		<input type="radio"/>		<input checked="" type="radio"/>	<input type="radio"/>		<input type="radio"/>
MSH2 seq		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
MSH2 del/dup		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
MSH6 seq		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
MSH6 del/dup		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
PMS2 seq		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
PMS2 del/dup		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
EPCAM del/dup		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
Constitutive MLH1		<input type="radio"/>		<input type="radio"/>	<input type="radio"/>		<input checked="" type="radio"/>
Methylation Analysis							

Family member(s) tested: Yes No Unknown

Relative	Date	Result	
Son	12/20/2012	Negative	Delete
Sister - full	1/15/2013	Positive	Delete
<input type="text"/>	<input type="text"/>	<input type="text"/>	Add



Initial Research Questions

- Number of newly diagnosed CRC and EC screened and % positive by protocol
- Frequency of mutations in LS genes by: age of diagnosis, tumor characteristics, family history and screening protocols
- Average number of family members pursuing cascade testing

Status

- Database revisions completed
- Database under construction via OMNI
- Data use agreements – through OMNI
- IRB approval under review through UCSF
 - Linked and unlinked options for patient identifiers
- Data transfer template developed by UCSF
 - Several entities able/willing to dump large data sets – first step
- Finalization of data entry manual

Question?

